Notice2025-19705

Lawrence Michael Willis, D.D.S.; Decision and Order

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
October 30, 2025

Issuing agencies

Justice DepartmentDrug Enforcement Administration

Full Text

<html>
<head>
<title>Federal Register, Volume 90 Issue 208 (Thursday, October 30, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 208 (Thursday, October 30, 2025)]
[Notices]
[Pages 48898-48900]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-19705]



[[Page 48898]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Lawrence Michael Willis, D.D.S.; Decision and Order

    On November 20, 2024, the Drug Enforcement Administration (DEA or 
Government) issued an Order to Show Cause (OSC) to Lawrence Michael 
Willis, D.D.S., of Commerce City, Colorado (Registrant). OSC, at 1, 6; 
Request for Final Agency Action (RFAA), Exhibit (RFAAX) 1, at 1, 6. The 
OSC proposed the revocation of Registrant's DEA Certificate of 
Registration No. AW1335822, alleging that Registrant has committed acts 
that are inconsistent with the public interest. OSC, at 1 (citing 21 
U.S.C. 823(g)(1); 824(a)(4)).\1\ More specifically, the OSC alleged 
that Registrant repeatedly violated Colorado law by failing to register 
for and query the Colorado Prescription Drug Monitoring Program, in 
violation of Colo. Rev. Stat. Sec. Sec.  12-30-109(1)(b), 12-280-
403(2)(a), 12-280-404(4)(a), 12-280-404(4)(a.5). OSC, at 2-4.
---------------------------------------------------------------------------

    \1\ Based on the Government's submissions in its RFAA dated 
February 4, 2025, the Agency finds that service of the OSC on 
Registrant was adequate. Specifically, the Declaration from a DEA 
Diversion Investigator (DI) indicates that on December 3, 2024, the 
DI, along with a second Diversion Investigator, traveled to 
Registrant's registered address and personally served the OSC on 
Registrant. RFAAX 2, at 1.
---------------------------------------------------------------------------

    On February 4, 2025, the Government submitted an RFAA requesting 
that the Agency issue a default final order revoking Registrant's 
registration. RFAA, at 4-5. After carefully reviewing the entire record 
and conducting the analysis as set forth in more detail below, the 
Agency grants the Government's request for final agency action and 
revokes Registrant's registration.

I. Default Determination

    Under 21 CFR 1301.43, a registrant entitled to a hearing who fails 
to file a timely hearing request ``within 30 days after the date of 
receipt of the [OSC] . . . shall be deemed to have waived their right 
to a hearing and to be in default'' unless ``good cause'' is 
established for the failure. 21 CFR 1301.43(a) & (c)(1). In the absence 
of a demonstration of good cause, a registrant who fails to timely file 
an answer also is ``deemed to have waived their right to a hearing and 
to be in default.'' 21 CFR 1301.43(c)(2). Unless excused, a default is 
deemed to constitute ``an admission of the factual allegations of the 
[OSC].'' 21 CFR 1301.43(e).
    Here, the OSC notified Registrant of his right to file a written 
request for hearing, and that if he failed to file such a request, he 
would be deemed to have waived his right to a hearing and be in 
default. RFAAX 1, at 4-5 (citing 21 CFR 1301.43). According to the 
Government's unrebutted RFAA, Registrant failed to request a hearing 
and the Agency so finds. RFAA, at 2. Thus, the Agency finds that 
Registrant is in default and therefore is deemed to have admitted to 
the factual allegations in the OSC. 21 CFR 1301.43(e).

II. Applicable Law

    As the Supreme Court stated in Gonzales v. Raich, 545 U.S. 1 
(2005), ``the main objectives of the [Controlled Substances Act (CSA)] 
were to conquer drug abuse and control the legitimate and illegitimate 
traffic in controlled substances.'' 545 U.S. at 12. Gonzales explained 
that:
    Congress was particularly concerned with the need to prevent the 
diversion of drugs from legitimate to illicit channels. To effectuate 
these goals, Congress devised a closed regulatory system making it 
unlawful to manufacture, distribute, dispense, or possess any 
controlled substance except in a manner authorized by the CSA . . . . 
The CSA and its implementing regulations set forth strict requirements 
regarding registration, labeling and packaging, production quotas, drug 
security, and recordkeeping.
    Id. at 12-14.
    The OSC's allegations concern the CSA's ``statutory and regulatory 
provisions . . . mandating . . . compliance with . . . prescription 
requirements'' and, therefore, go to the heart of the CSA's ``closed 
regulatory system'' specifically designed ``to conquer drug abuse and 
to control the legitimate and illegitimate traffic in controlled 
substances,'' and ``to prevent the diversion of drugs from legitimate 
to illicit channels.'' Id. at 12-14, 27.

A. Allegation That Registrant Failed To Register for and Query the 
Colorado Prescription Drug Monitoring Program

    Colorado regulations require that every practitioner licensed in 
the state register for and maintain an account with the Colorado 
Prescription Drug Monitoring Program (PDMP) and query the Colorado PDMP 
prior to prescribing any opioid or benzodiazepine. Colo. Rev. Stat. 
Sec. Sec.  12-30-109(1)(b), 12-280-403(2)(a), 12-280-404(4)(a), 12-280-
404(4)(a.5).

III. Findings of Fact

    The Agency finds that, in light of Registrant's default, the 
factual allegations in the OSC are deemed admitted.\2\ 21 CFR 
1301.43(e). Accordingly, Registrant is deemed to have admitted to each 
of the following facts and the Agency finds unrebutted evidence 
thereof.
---------------------------------------------------------------------------

    \2\ According to the Controlled Substances Act (CSA), 
``[f]indings of fact by the [DEA Administrator], if supported by 
substantial evidence, shall be conclusive.'' 21 U.S.C. 877. Here, 
where Applicant is found to be in default, all the factual 
allegations in the OSC are deemed to be admitted. These uncontested 
and deemed admitted facts constitute evidence that exceeds the 
``substantial evidence'' standard of 21 U.S.C. 877; it is unrebutted 
evidence.
---------------------------------------------------------------------------

    Registrant admits that as a licensed practitioner in Colorado, he 
was required to registered with the Colorado PDMP. RFAAX 1, at 2. 
Despite this requirement, he failed to timely register for the Colorado 
PDMP, and on December 16, 2022, the Colorado Dental Board issued a 
disciplinary order against him for his failure to register for the 
Colorado PDMP. Id. at 3. Registrant admits that from at least July 2018 
through at least June 2023, he failed to register for the Colorado 
PDMP. Id. at 3-4.
    Registrant further admits that as a licensed practitioner in 
Colorado, he was required to query the Colorado PDMP prior to issuing 
prescriptions for opioids and benzodiazepines. Id. at 3. Registrant 
admits that from at least July 2018 through at least June 2023, he 
failed to query the Colorado PDMP prior to issuing numerous opioid and 
benzodiazepine prescriptions to his patients. Id. at 3-4.
    Specifically, Registrant admits that between July 2018 and June 
2023, he issued the following prescriptions without querying the PDMP: 
\3\ approximately three prescriptions for hydrocodone-acetaminophen 
7.5-325 mg (a Schedule II opiate) and 67 prescriptions for hydrocodone-
acetaminophen 10-325 mg to M.G; approximately 27 prescriptions for

[[Page 48899]]

hydrocodone-acetaminophen 10-325 mg to R.H.; approximately one 
prescription for diazepam 5 mg (a Schedule IV benzodiazepine), three 
prescriptions for hydrocodone-acetaminophen 7.5-325 mg, and 40 
prescriptions for hydrocodone-acetaminophen 10-325 mg to A.M.; 
approximately 26 prescriptions for hydrocodone-acetaminophen 10-325 mg 
to J.M.; and approximately 28 prescriptions for hydrocodone-
acetaminophen 10-325 mg to L.W. Id. at 3-4.
---------------------------------------------------------------------------

    \3\ These prescriptions were all issued by Registrant's 
receptionist and patient, M.G., using Registrant's prescription pad. 
Id. at 3-4. Registrant admits that he permitted M.G. to sign and 
authorize prescriptions on his behalf. Id. at 3. Although the 
Government alleges that Registrant's delegation of his prescribing 
authority is evidence that Registrant ``failed to take appropriate 
measures to safeguard against potential misuse, abuse, and/or 
diversion of controlled substances,'' the Government does not cite 
any specific violations of state or federal law or explain the nexus 
to public interest factors B and D (see infra IV.A). Id. at 3-4. 
Although the Agency notes that this conduct is clearly unlawful, 
see, e.g., Neeraj B. Shah, M.D., 89 FR 84195, 84197 n.11 (2024) 
(``[W]here a registrant's actions allow an unregistered person to 
prescribe controlled substances, as Respondent did here, the 
registrant can be found in violation of 21 CFR 1306.04(a)''), the 
Agency need not adjudicate these allegations because there is other 
substantial evidence on the record demonstrating that Registrant's 
registration is inconsistent with the public interest.
---------------------------------------------------------------------------

    In consideration of the above, the Agency finds unrebutted record 
evidence that Registrant failed to register for the Colorado PDMP and 
that Registrant issued at least 195 prescriptions for opioids and 
benzodiazepines without first querying the Colorado PDMP.

IV. Public Interest Determination

A. Legal Background on Public Interest Determinations

    When the CSA's requirements are not met, the Attorney General ``may 
deny, suspend, or revoke [a] registration if . . . the [registrant's] 
registration would be `inconsistent with the public interest.' '' 
Gonzales v. Oregon, 546 U.S. 243, 251 (2006) (quoting 21 U.S.C. 
824(a)(4)). In the case of a ``practitioner,'' Congress directed the 
Attorney General to consider five factors in making the public interest 
determination. Id.; 21 U.S.C. 823(g)(1)(A-E).\4\
---------------------------------------------------------------------------

    \4\ The five factors are:
    (A) The recommendation of the appropriate State licensing board 
or professional disciplinary authority.
    (B) The [registrant's] experience in dispensing, or conducting 
research with respect to controlled substances.
    (C) The [registrant's] conviction record under Federal or State 
laws relating to the manufacture, distribution, or dispensing of 
controlled substances.
    (D) Compliance with applicable State, Federal, or local laws 
relating to controlled substances.
    (E) Such other conduct which may threaten the public health and 
safety.
    21 U.S.C. 823(g)(1)(A-E).
---------------------------------------------------------------------------

    The five factors are considered in the disjunctive. Gonzales v. 
Oregon, 546 U.S. at 292-93 (Scalia, J., dissenting) (``It is well 
established that these factors are to be considered in the 
disjunctive,'' quoting In re Arora, 60 FR 4447, 4448 (1995)); Robert A. 
Leslie, M.D., 68 FR 15227, 15230 (2003). Each factor is weighed on a 
case-by-case basis. David H. Gillis, M.D., 58 FR 37507, 37508 (1993). 
Any one factor, or combination of factors, may be decisive, David H. 
Gillis, M.D., 58 FR at 37508, and the Agency ``may give each factor the 
weight . . . deem[ed] appropriate in determining whether a registration 
should be revoked or an application for registration denied.'' Morall 
v. Drug Enf't Admin., 412 F.3d. 165, 185 n.2 (D.C. Cir. 2005) 
(Henderson, J., concurring) (quoting Robert A. Smith, M.D., 70 FR 
33207, 33208 (2007)); see also Penick Corp. v. Drug Enf't Admin., 491 
F.3d 483, 490 (D.C. Cir. 2007).
    Moreover, while the Agency is required to consider each of the 
factors, it ``need not make explicit findings as to each one.'' MacKay 
v. Drug Enf't Admin., 664 F.3d 808, 816 (10th Cir. 2011) (quoting 
Volkman v. U.S. Drug Enf't Admin., 567 F.3d 215, 222 (6th Cir. 2009)); 
Jones Total Health Care Pharmacy, LLC v. Drug Enf't Admin., 881 F.3d 
823, 830 (11th Cir. 2018); Hoxie v. Drug Enf't Admin., 419 F.3d 477, 
482 (6th Cir. 2005). ``In short, . . . the Agency is not required to 
mechanically count up the factors and determine how many favor the 
Government and how many favor the registrant. Rather, it is an inquiry 
which focuses on protecting the public interest; what matters is the 
seriousness of the registrant's misconduct.'' Jayam Krishna-Iyer, M.D., 
74 FR 459, 462 (2009). Accordingly, as the Tenth Circuit has 
recognized, Agency decisions have explained that findings under a 
single factor can support the revocation of a registration. MacKay, 664 
F.3d at 821.
    The Government has the burden of proof in this proceeding. 21 CFR 
1301.44(e).

B. Registrant's Registration Is Inconsistent With the Public Interest

    While the Agency has considered all the public interest factors of 
21 U.S.C. 823(g)(1),\5\ the Government's evidence in support of its 
prima facie case is confined to Factor D.\6\ OSC, at 2-4. Evidence is 
considered under Factor D when it reflects compliance or non-compliance 
with laws related to controlled substances. Kareem Hubbard, M.D., 87 FR 
21156, 21162 (2022).
---------------------------------------------------------------------------

    \5\ As to Factor A, there is no record evidence of disciplinary 
action against Registrant's state medical license. 21 U.S.C. 
823(g)(1)(A). State authority to practice medicine is ``a necessary, 
but not a sufficient condition for registration.'' Robert A. Leslie, 
M.D., 68 FR at 15230. Therefore, ``[t]he fact that the record 
contains no evidence of a recommendation by a state licensing board 
does not weigh for or against a determination as to whether 
continuation of the Respondent's DEA certification is consistent 
with the public interest.'' Roni Dreszer, M.D., 76 FR 19434, 19444 
(2011). As to Factor C, there is no evidence in the record that 
Registrant has been convicted of any federal or state law offense 
``relating to the manufacture, distribution, or dispensing of 
controlled substances.'' 21 U.S.C. 823(g)(1)(C). However, as Agency 
cases have noted, ``the absence of such a conviction is of 
considerably less consequence in the public interest inquiry'' and 
is therefore not dispositive. Dewey C. MacKay, M.D., 75 FR at 49973. 
As to Factor E, the Government's evidence fits squarely within the 
parameters of Factors B and D and does not raise ``other conduct 
which may threaten the public health and safety.'' 21 U.S.C. 
823(g)(1)(E). Accordingly, Factor E does not weigh for or against 
Registrant.
    \6\ The OSC also alleges that Factor B weighs against 
Registrant's continued registration, but it does not specify what 
factual or legal allegations are relevant to the Agency's Factor B 
analysis. See supra n.3.
---------------------------------------------------------------------------

    Here, as found above, Registrant is deemed to have admitted and the 
Agency finds that Registrant failed to register for the Colorado PDMP 
and that Registrant issued at least 195 prescriptions for opioids and 
benzodiazepines without first querying the Colorado PDMP. Accordingly, 
the Agency finds substantial record evidence that Registrant violated 
Colo. Rev. Stat. Sec. Sec.  12-30-109(1)(b), 12-280-403(2)(a), 12-280-
404(4)(a), and 12-280-404(4)(a.5). The Agency further finds that after 
considering the factors of 21 U.S.C. 823(g)(1), Registrant's continued 
registration is ``inconsistent with the public interest.'' 21 U.S.C. 
824(a)(4). Accordingly, the Government satisfied its prima facie burden 
of showing that Registrant's continued registration would be 
``inconsistent with the public interest.'' 21 U.S.C. 824(a)(4). The 
Agency also finds that Registrant has presented no mitigating evidence 
to rebut the Government's prima facie case. Thus, the only remaining 
issue is whether, in spite of Registrant's misconduct, he can be 
trusted with a registration.

V. Sanction

    Where, as here, the Government has met the burden of showing that 
Registrant's registration is inconsistent with the public interest, the 
burden shifts to Registrant to show why he can be entrusted with a 
registration. Morall, 412 F.3d. at 174; Jones Total Health Care 
Pharmacy, LLC v. Drug Enf't Admin., 881 F.3d 823, 830 (11th Cir. 2018); 
Garrett Howard Smith, M.D., 83 FR 18882, 18904 (2018). The issue of 
trust is necessarily a fact-dependent determination based on the 
circumstances presented by the individual registrant. Jeffrey Stein, 
M.D., 84 FR 46968, 46972 (2019); see also Jones Total Health Care 
Pharmacy, 881 F.3d at 833. Moreover, as past performance is the best 
predictor of future performance, the Agency requires that a registrant 
who has committed acts inconsistent with the public interest accept 
responsibility for those acts and demonstrate that he will not engage 
in future misconduct. See Jones Total Health Care Pharmacy, 881 F.3d at 
833; ALRA Labs, Inc. v. Drug Enf't Admin.,

[[Page 48900]]

54 F.3d 450, 452 (7th Cir. 1995). The Agency requires a registrant's 
unequivocal acceptance of responsibility. Janet S. Pettyjohn, D.O., 89 
FR 82639, 82641 (2024); Mohammed Asgar, M.D., 83 FR 29569, 29573 
(2018); see also Jones Total Health Care Pharmacy, 881 F.3d at 830-31. 
In addition, a registrant's candor during the investigation and hearing 
is an important factor in determining acceptance of responsibility and 
the appropriate sanction. See Jones Total Health Care Pharmacy, 881 
F.3d at 830-31; Hoxie, 419 F.3d at 483-84. Further, the Agency 
considers the egregiousness and extent of the misconduct as significant 
factors in determining the appropriate sanction. See Jones Total Health 
Care Pharmacy, 881 F.3d at 834 & n.4. The Agency also considers the 
need to deter similar acts by a Registrant and by the community of 
registrants. Jeffrey Stein, M.D., 84 FR at 46972-73.
    Here, Registrant did not request a hearing or answer the 
allegations in the OSC, and was therefore deemed to be in default. See 
supra I. To date, Registrant has not filed a motion with the Office of 
the Administrator to excuse the default. 21 CFR 1301.43(c)(1). 
Registrant has thus failed to answer the allegations contained in the 
OSC and has not otherwise availed himself of the opportunity to refute 
the Government's case.\7\ As such, Registrant has not accepted 
responsibility for the proven violations, has made no representations 
regarding his future compliance with the CSA, and has not demonstrated 
that he can be trusted with registration. Accordingly, the Agency will 
order the revocation of Registrant's registration.
---------------------------------------------------------------------------

    \7\ Notably, and as described supra III, Registrant failed to 
register for the Colorado PDMP even after he was disciplined by the 
Colorado Dental Board for his failure to register. RFAAX 1, at 3-4.
---------------------------------------------------------------------------

Order

    Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 
U.S.C. 824(a) and 21 U.S.C. 823(g)(1), I hereby revoke DEA Certificate 
of Registration No. AW1335822 issued to Lawrence Michael Willis, D.D.S. 
Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 
21 U.S.C. 823(g)(1), I hereby deny any pending applications of Lawrence 
Michael Willis, D.D.S., to renew or modify this registration, as well 
as any other pending application of Lawrence Michael Willis, D.D.S., 
for additional registration in Colorado. This Order is effective 
December 1, 2025.

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
October 9, 2025, by Administrator Terrance Cole. That document with the 
original signature and date is maintained by DEA. For administrative 
purposes only, and in compliance with requirements of the Office of the 
Federal Register, the undersigned DEA Federal Register Liaison Officer 
has been authorized to sign and submit the document in electronic 
format for publication, as an official document of DEA. This 
administrative process in no way alters the legal effect of this 
document upon publication in the Federal Register.

Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2025-19705 Filed 10-29-25; 8:45 am]
BILLING CODE 4410-09-P


</pre></body>
</html>
Indexed from Federal Register on October 30, 2025.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.